Ti Cai

Ti Cai is an experienced professional in the field of immuno-oncology and clinical biomarkers, currently serving as Senior Director and Head of Immuno-Oncology Clinical Biomarkers at EMD Serono, Inc. since March 2015. In this role, Ti Cai leads the clinical biomarker and companion diagnostic development for the avelumab program. Prior experience includes positions at Celgene as Associate Director of Translational Medicine, Sanofi as Principal Research Investigator, Amgen as Scientist/Sr. Scientist in Oncology Research, and AVEO Oncology as Scientist in Translational Research. Ti Cai holds a Postdoctoral Fellowship from Stanford University School of Medicine, a PhD in Biochemistry and Molecular Biology from Upstate Medical University, and a BS in Biochemistry from Fudan University.